Trump signs order to reclassify marijuana, ease research restrictions

President Trump signed an executive order directing the attorney general and DEA to fast-track reclassification of marijuana from Schedule I to Schedule III, lowering federal restrictions and easing requirements for medical and clinical research. The move aligns federal policy more closely with many state legalizations, could materially reduce research and regulatory barriers for cannabis-sector companies, and follows an incomplete Biden-era reclassification effort while drawing GOP criticism.

Analysis

Market structure: Rescheduling to Schedule III disproportionately benefits US-listed multi-state operators (MSOs), cannabis-focused ETFs (MJ) and pharmaceutical/biotech groups able to run clinical trials; expect these names to capture more M&A and licensing fees as barriers to FDA-quality R&D fall. Lower regulatory friction will favor vertically integrated players and branded CP companies over commodity flower producers, pressuring spot wholesale prices but improving branded pricing power over 12–36 months.

Risk assessment: Key tail risks are political reversal or litigation (Republican Senate pushback) and the tax-code trap—Section 280E still applies to Schedule I drugs and may not automatically change, meaning immediate cash-flow improvement is uncertain. Timeline: expect 0–30 day headline volatility, 60–180 day DEA/DOJ rulemaking and 12–36 month structural margin/m&a effects; catalysts include Federal Register notices, IRS guidance on 280E and any FDA drug-approval partnerships.

Trade implications: Tactical plays favor 6–12 month directional exposure to US legalization beneficiaries (MJ ETF, TLRY) and option structures to cap downside; long-term winners are MSOs with retail footprints and pharma tie-ups. Relative value: overweight US MSO/extraction/ancillary names versus pure-play Canadian LPs that face oversupply and weaker retail distribution.

Contrarian angles: The market underestimates the 280E/IRS dependency—rescheduling alone may not free MSO cashflows for dividends or buybacks for 6–18 months, so early rallies can be faded. Historical parallels (alcohol/tobacco consolidation) suggest multi-year roll-up and margin recovery, but expect 20–40% drawdowns on headline risk before a structural rerating.

Key Decisions for Investors

• Establish a 2–3% portfolio long in ETFMG Alternative Harvest (MJ) within 5 trading days to capture broad U.S. upside; hedge with a 6–12 month 1:1 put (protect ~15% downside) if entry is on >10% intraday pop.
• Buy a 12-month TLRY call spread (e.g., buy 1x ATM LEAP, sell 1x ~1.5x strike) sized 0.75–1.25% of portfolio to gain leveraged upside while capping premium; increase size by 50% if DEA posts a proposed rule within 60 days.
• Initiate a relative-value pair: long TLRY (1.0% portfolio) and short CGC (1.0% portfolio) to express US regulatory re-rate vs Canadian oversupply exposure; mark-to-market weekly and stop-loss at 20% adverse move per leg.
• If DOJ/DEA publishes a formal rescheduling timeline or IRS issues 280E relief within 90 days, add an incremental 1–2% to US MSO/ETF exposure and rotate out of low-growth Canadian LP names (trim or exit CGC/ACB) over the subsequent 30 days.